secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001683168-24-002961
Event type: other_material
Sentiment:  neutral
Materiality: 0.78
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals shareholders approve 4x increase in authorized shares, reverse split authorization
--------------------------------------------------------------------------------

- Authorized common shares increased from 75M to 300M; 3.5M shares added to 2020 Equity Plan (total 4,345,800).
- Board authorized to effect reverse stock split from 1:2 to 1:50 within one year.
- Stockholders approved repricing of 3.756M warrants from $1.28 to $0.30 and extension to Feb 2029.
- All six director nominees elected; board committees appointed (Audit, Comp, Nominating/Governance).
- Ratified MaloneBailey LLP as independent auditor for FY 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/0001683168-24-002961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-002961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer